Earnings Releases·Nov 13, 2026, 8:10 AM ET

Biofrontera Inc. — Third Quarter 2026 Earnings Summary

Net product revenue rose 29.8% year-over-year to $9.1 million for the quarter, while gross margin improved to 74.4% from 70.7% in the prior-year period, driven by a lower cost structure despite ITC-related inventory write-downs.
The company reported a net loss of $6.4 million ($0.42 per share) for the quarter, narrowing from $6.6 million ($0.62 per share) in the prior year, with adjusted EBITDA improving to $(5.5) million from $(6.0) million.
FDA approval for Ameluz in superficial basal cell carcinoma (sBCC) was secured on September 9, 2026, with commercialization planned for late Q4 2026 into Q1 2027, following a U.S. Customs ruling clearing the redesigned RhodoLED XL-C lamp.
Cash and cash equivalents declined to $3.2 million as of September 30, 2026, from $6.4 million at year-end 2025, while the company maintains no bank debt and holds $4.7 million in convertible notes maturing in November 2027.